Page 334 - Haematologica March 2020

C. Becattini et al.
chemotherapy. J Thromb Haemost. 2007;5
(3):632-634.
7. Di Nisio M, Porreca E, Candeloro M, De
Tursi M, Russi I, Rutjes AW. Primary pro- phylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2016;15(2): CD008500.
8. Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagu- lants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452- e466.
9. Lyman GH, Bohlke K, Falanga A. American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treat- ment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015;11(3):e442-e444.
10. Levine MN, Gu C, Liebman HA, et al. A ran- domized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012;10(5):807-814.
11. Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboem- bolism in patients with cancer. N Engl J Med. 2019;380(8):711-719.
12. Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720-728.
13. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PloS Med. 2009;6(7): e1000097.
14. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, For GG; Evidence-based medicine teaching tips working group. Tips for learn- ers of evidence based medicine: 3. Measures of observer variability (kappa statistic). CMAJ. 2004;171(11):1369-1373.
15. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of random- ized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
16. Egger M, Smith GD, Altman DG, Chalmers I. Systematic Reviews in Health Care: Meta- Analysis in Context. 2nd ed. London, England. BMJ Books; 2001.
17. Higgins JP, Thompson SG. Quantifying het- erogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
18. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101-129.
19. Levine M, Hirsh J, Gent M, et al. Double- blind randomised trial of a very-low-dose warfarin for prevention of thromboem- bolism in stage IV breast cancer. Lancet. 1994;343(8902):886-889.
20. Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute
lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost. 2003;90(2):235-244.
21. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of throm- boembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a ran- domised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943-949.
22. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-con- trolled trial of dalteparin low-molecular- weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost. 2010;8(9):1959- 1965.
23. Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119(4):933-939.
24. Haas SK, Freund M, Heigener D, et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost. 2012;18(2):159-165.
25. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601-609.
26. Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dal- teparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012;48(9):1283- 1292.
27. Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol. 2015;33(18):2028-2034.
28. Zwicker JI, Liebman HA, Bauer KA, et al. Prediction and prevention of thromboem- bolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol. 2013;160(4):530-537.
29. Khorana AA, Francis CW, Kuderer NM, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboem- bolism: a randomized trial. Thromb Res. 2017;151:89-95.
30. Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer. 1994;74(1):38-45.
31. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22(10):1944-1948.
32. Altinbas M, Coskun HS, Er O, et al. A ran- domized clinical trial of combination chemotherapy with and without low-mole- cular-weight heparin in small cell lung can-
cer. J Thromb Haemost. 2004;2(8):1266-
1271.
33. Klerk CP, Smorenburg SM, Otten HM, et al.
The effect of low molecular weight heparin on survival in patients with advanced malig- nancy. J Clin Oncol. 2005;23(10):2130-2135.
34. Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006;81(6):758-767.
35. van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol. 2011;29(15):2071-2076.
36. Elit LM, Lee AY, Parpia S, et al. Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. Thromb Res. 2012;130(6):894-900.
37. Lecumberri R, López Vivanco G, Font A, et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thromb Res. 2013;132(6):666-670.
38. Macbeth F, Noble S, Evans J, et al. Randomized phase III trial of standard ther- apy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. J Clin Oncol. 2016;34 (5):488-494.
39. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest. 2001;119 (1Suppl):22S-38S.
40. Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospi- talized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198-3225.
41. Verso M, Chiari R, Mosca S, et al. Incidence of CT-scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma. Thromb Res. 2015;136(5):924-927.
42. Zugazagoitia J, Biosca M, Oliveira J, et al. Incidence, predictors and prognostic signifi- cance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer. Eur Respir J. 2018;51(5).
43. Ng TL, Smith DE, Mushtaq R, et al. ROS1 gene rearrangements are associated with an elevated risk of peridiagnosis thromboem- bolic events. J Thorac Oncol. 2019;14(4): 596-605
44. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.
45. Mulder FI, Candeloro M, Kamphuisen PW, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta- analysis. Haematologica. 2019;104(6):1277- 1287.
50. Khorana AA, O'Connell C, Agnelli G, Liebman HA, Lee AY. Incidental venous thromboembolism in oncology patients. J Thromb Haemost. 2012;10(12):2602-2604.
848
haematologica | 2020; 105(3)